Clinical trial · Interventional
Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus
Surgical Resection Versus Best Supportive Care for Resectable Hepatocellular Carcinoma Invading the First Branch of Portal Vein
NCT01600196CI-TRIAL-00036674terminatedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the long-term efficacy and safety of surgical resection compared with best supportive care in patients with resectable hepatocellular carcinoma (HCC) with portal venous thrombus (PVTT) in the first branch of portal vein.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Liver resection plus Thrombectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Resection arm
- description
- Liver resection Plus Thrombectomy
- interventionNames
- Procedure: Liver resection plus Thrombectomy
- type
- NO_INTERVENTION
- label
- Best support care arm
- description
- Best supportive care
Primary outcomes (1)
- measure
- Survival time
- timeFrame
- 5-years
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * The diagnosis of HCC was made according to AASLD guidelines * Main tumor ≥ 7 cm * Imaging confirmed the presence of PVTT in the first branches but not * Extend into the main trunk of portal vein * Eastern Co-operative Group performance * Resectable disease Exclusion Criteria: * Child-Pugh class B or C liver cirrhosis * An American Society of Anesthesiologists (ASA) score ≥ 3 * Extrahepatic metastasis * Patients had access to sorafenib.
References
Publications (1)
- BACKGROUNDLe Treut YP, Hardwigsen J, Ananian P, Saisse J, Gregoire E, Richa H, Campan P. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg. 2006 Jun;10(6):855-62. doi: 10.1016/j.gassur.2005.12.011. PMID 16769542